Better Medicines. Faster.

We move at the speed of AI. X-37 accelerates the drug discovery process by using state-of-the art technology to efficiently explore the vast universe of drug-like compounds in silico, while our veteran drug development team guides the journey from target selection to clinical study design and FDA approval.

X-37 Announces $14.5 Million Series A

Read More

Drugging the Undruggable

Our AI-driven approach to drug development lets us work on the most difficult-to-target proteins across the broadest possible chemical space. We focus on targets of high therapeutic value that have challenged the conventional drug discovery industry – sparking new hope for safe, effective therapies in these diseases. Our current targets have established causal roles in autoimmune disease, cancer, and anticoagulation.

Learn More

We Know Drug Development

X-37’s world-class management team has successfully led the development and regulatory approval of a wide range of therapeutics for leading biotechnology and pharmaceutical companies.

More About Us

David Collier

CEO

Andrew Perlman

Head of Non-Clinical Development

Anie Roche

General Counsel

Accelerating Drug Discovery

We leverage the latest advances in drug discovery technology by building partnerships with AI companies that specialize in cutting-edge technology designed to identify small molecules that can potently and selectively bind difficult-to-drug targets. Our flexible approach allows us to select the best technology for every target in our pipeline.

Learn More

info@x37.ai